4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Postherpetic Neuralgia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 99 ongoing clinical trials involving Postherpetic Neuralgia
Of the 99 trials,41 trials are in Phase III
Furthermore, 20 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Postherpetic Neuralgia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Postherpetic Neuralgia, a gastrointestinal condition. The largest number of ongoing clinical trials for Postherpetic Neuralgia is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Postherpetic Neuralgia-related drug trials.

Postherpetic Neuralgia related clinical trial sponsor

Lexicon Pharmaceuticals Inc, Odense University Hospital, Shanghai Jiao Tong University, Nippon Zoki Pharmaceutical Co Ltd, and Daana Pharmaceutical Company are among other notable clinical trial sponsors involved in Postherpetic Neuralgia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Postherpetic Neuralgia

Varicella zoster vaccine (Shingrix/GSK-1437173A), Pregabalin (Lyrica), and Valacyclovir hydrochloride (Valtrex, Zelitrex, Valherpes, Virval, Zimivir, Rapivir) are among the key marketed drugs involving Postherpetic Neuralgia.

Varicella zoster vaccine (Shingrix/GSK-1437173A) is a sterile, non-live vaccine of recombinant varicella zoster virus surface glycoprotein E (VZV gE) produced in Chinese Hamster Ovarian (CHO) cells by recombinant DNA technology. It is adjuvanted with AS01B containing plant extract Quillaja saponaria Molina, fraction 21 (QS-21), a liposomal formulation and acts as an immuno protective agent. It is formulated as injectable lyophilized powder for suspension, for intramuscular route of administration. Shingrix is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older and adults 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. Varicella zoster vaccine was first approved in 2017 and is marketed globally including the US, the UK, France, and Germany by GlaxoSmithKline Plc.

Pregabalin (Lyrica) is an anticonvulsant drug. It functions via Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Blocker; Voltage Dependent Calcium Channel Subunit Alpha2/Delta2 (CACNA2D2) Blocker mechanism of action. It is formulated in the form of capsule and solution for oral administration. Pregabalin is indicated for the treatment of Postherpetic Neuralgia and several other indications including Epilepsy, Neuropathic Pain (Neuralgia), Pain, Anxiety Disorders, Partial Seizure, Generalized Anxiety Disorder (GAD), Fibromyalgia (Fibromyalgia Syndrome), Diabetic Neuropathic Pain, and Generalized Seizures. Pregabalin was first approved in 2004 and is marketed globally including the US, the UK, France, and Germany by several pharma giants including Viatris Inc, and Greenstone LLC.